Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07528014

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Status
Recruiting
Phase
Study type
Observational
Enrollment
5,000 (estimated)
Sponsor
Salma Health, Inc. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Conditions

Timeline

Start date
2026-03-25
Primary completion
2036-03-01
Completion
2037-03-01
First posted
2026-04-14
Last updated
2026-04-14

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT07528014. Inclusion in this directory is not an endorsement.

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1 (NCT07528014) · Clinical Trials Directory